Testing alpibectir plus ethionamide for new TB
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests an experimental oral TB drug called alpibectir given together with ethionamide for people with newly diagnosed lung TB. The goal is to see how well the combination works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lung TB and have not yet started treatment.
- Your TB bacteria are sensitive to the drugs rifampicin and isoniazid.
- You can produce enough sputum (phlegm) for testing.
- You are willing to use effective birth control during the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests personalized TB treatment schedules based on your individual risk factors. Researchers want to see if matching treatment intensity to your specific situation helps cure TB while minimizing side effects.
This study tests whether adding the cholesterol drug atorvastatin to standard TB treatment helps people recover faster. It is for people with newly diagnosed, drug-sensitive tuberculosis who have not yet started treatment.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This study tests new, faster ways to diagnose tuberculosis (TB) using samples like sputum (mucus from your lungs), tongue swabs, and urine. It aims to see if these new tests can find TB more accurately than current methods, which could help you get the right treatment sooner.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This trial tests a new drug, RESP30TB, to see if it is safe, tolerable, and can quickly kill TB bacteria in people with newly diagnosed, rifampicin-susceptible pulmonary TB. You may be eligible if you can produce sputum and meet other health criteria.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.